Rilpivirine CAS NO.500287-72-9

In stock ,>98% purity with low price. If you need HNMR\HPLC,please contact us! 

1.we are direct manufacturer and we have 7 years experience in this aera.
2.we can provide competitive price for every customer and guarantee the quality of our goods.
3.Specials are possible when client's order is big enough, including the discount policy;
4.we promise we will return your money if our product don't have effect.
5.Our company promise to deliver clients' package to his hands safely, or we'll cover the total loss and reship in time;
6. Our customers may buy our products again after they use our sample.

Rilpivirine is a pharmaceutical drug, developed by Tibotec, for the treatment of HIV infection. It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz. Rilpivirine entered phase III clinical trials in April 2008, and was approved for use in the United States in May 2011. A fixed-dose drug combining rilpivirine with emtricitabine and tenofovir, was approved by the U.S. Food and Drug Administration in August 2011 under the brand name Complera.

Tianjin Kailiqi Biopharma Technology Co., Ltd, is a professional manufacturer specialized in the production and distribution of active pharmaceutical ingredients and intermediates. Our company has strong R&D ability and production experience to provide the customers new APIs. We specialize in developing innovative processes for the synthesis of a wide range of products. We also undertake custom synthesis and contract manufacturing.if you are interest in,pls contact with me,we also have Lab,specifical in some hard synthesis.